Unichem Laboratories · NSE: UNICHEMLAB · BSE: 506690

Q3 FY22 results · Oct–Dec 2021

Unichem Laboratories reported revenue from operations of ₹311.31 crore (down 4.6% from Q3 FY21) and net loss of ₹14.10 crore for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY22	Q3 FY21	YoY	Q2 FY22	QoQ
Revenue from operations	311.31	326.28	−4.6%	290.66	+7.1%
Other income	14.66	15.61	−6.1%	2.65	+452.8%
Total income	325.96	341.89	−4.7%	293.31	+11.1%
Profit before share of associates & JVs and tax	(10.64)	23.64	Turned loss	(15.30)	Loss narrowed
Share of profit/(loss) of associates & JVs	(0.77)	(0.15)		(0.21)
Net profit for the period	(14.10)	23.56	Turned loss	(12.82)	Loss widened
EPS, basic (₹)	(2.01)	3.35	Turned loss	(1.82)	Loss widened
Net margin (%)	-4.5	7.2		-4.4

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY22	Q3 FY21	YoY	Q2 FY22	QoQ
Revenue from operations	248.29	311.18	−20.2%	216.97	+14.4%
Other income	15.09	13.32	+13.2%	5.34	+182.5%
Total income	263.38	324.51	−18.8%	222.31	+18.5%
Profit before tax	(23.50)	25.61	Turned loss	(26.59)	Loss narrowed
Net profit for the period	(23.50)	30.43	Turned loss	(21.43)	Loss widened
EPS, basic (₹)	(3.34)	4.32	Turned loss	(3.04)	Loss widened
Net margin (%)	-9.5	9.8		-9.9

Consolidated

Filed with BSE: 29 Jan 2022, 20:59 IST
Board meeting: 29 Jan 2022
Period: 01 Oct 2021 to 31 Dec 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 29 Jan 2022, 20:59 IST
Board meeting: 29 Jan 2022
Period: 01 Oct 2021 to 31 Dec 2021
Review status: Unaudited
Source: XBRL filing on BSE